Optimal type 2 diabetes mellitus management: The randomised controlled OPTIMISE benchmarking study: Baseline results from six European countries

European Journal of Preventive Cardiology

Volumn 20, Issue 6, 2013, Pages 1095-1105

  Hermans, Michel P ^a   Brotons, Carlos ^b   Elisaf, Moses ^c   Michel, Georges ^d   Muls, Erik ^e   Nobels, Frank ^f  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Sardenya Primary Health Care Center   (Spain)

^c UNIVERSITY OF IOANNINA   (Greece)

^d CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f OLV Ziekenhuis   (Belgium)

Author keywords

benchmarking; glycated haemoglobin; LDL cholesterol; primary healthcare; quality of care; systolic blood pressure; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; BIGUANIDE DERIVATIVE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFANILAMIDE; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

BENCHMARKING; GLYCATED HAEMOGLOBIN; LDL-CHOLESTEROL; PRIMARY HEALTHCARE; QUALITY OF CARE; SYSTOLIC BLOOD PRESSURE; TYPE 2 DIABETES;

AGED; BENCHMARKING; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887064231     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312449414     Document Type: Article

References (63)

1. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J. 1991 ; 121: 1268-1273
2. Oldridge NB, Stump TE, Nothwehr FK, et al. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol. 2001 ; 54: 928-934
3. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998 ; 21: 160-178
4. Lipton RB, Liao Y, Cao G, Cooper RS, et al. Determinants of incident non-insulin-dependent diabetes mellitus among blacks and whites in a national sample. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1993 ; 138: 826-839
5. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003 ; 52: 1210-1214
6. Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005 ; 28: 2901-2907
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853
8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998 ; 317: 703-713
9. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005 ; 165: 1410-1419
10. PyoËdrälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997 ; 20: 614-620
11. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998 ; 98: 2513-2519
12. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999 ; 159: 2661-2667
13. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004 ; 141: 421-431
14. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 ; 321: 405-412
15. Gerstein HC, Pogue J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005 ; 48: 1749-1755
16. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
17. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
18. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360: 129-139
19. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009 ; 373: 1765-1772
20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 ; 351: 1755-1762
21. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 ; 288: 2981-2997
22. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 ; 370: 829-840
23. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000 ; 321: 412-419
24. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators; Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 ; 371: 117-125
25. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 ; 358: 580-591
26. Hermans MP. Prevention of microvascular diabetic complications by fenofibrate: Lessons from FIELD and ACCORD. Diab Vasc Dis Res. 2011 ; 8: 180-189
27. Andel M, Grzeszczak W, Michalek J, et al. A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey). Diabet Med.. 2008 ; 25: 1195-1203
28. Huppertz E, Pieper L, Klotsche J, et al. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes. 2009 ; 117: 6-14
29. Benhalima K and Mathieu C. Challenges in the management of hyperglycaemia in type 2 diabetes. Background paper in IDF Diabetes Atlas 4th edition International Diabetes Federation, 2009. (http://www.idf.org/diabetesatlas/ downloads/backgroundpapers).
30. Nobels F, Debacker N, Scheen AJ. Initiative to promote quality of care and epidemiology of diabetes mellitus. Rev Med Liege. 2005 ; 60: 624-627
31. Debacker N, Nobels F, Vandenberghe H, et al. Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience. Diabet Med. 2008 ; 25: 179-185
32. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model. JAMA. 2002 ; 288: 1775-1779
33. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness. The Chronic Care Model, part 2. JAMA. 2002 ; 288: 1909-1914
34. Bodenheimer T, Lorig K, Holman H, et al. Patient self-management of chronic disease in primary care. JAMA. 2002 ; 288: 2469-2475
35. Plsek PE. Section 1: Evidence-based quality improvement, principles, and perspectives. Quality improvement methods in clinical medicine. Pediatrics. 1999 ; 103: E203 - E214
36. Kiefe CI, Allison JJ, Williams OD, et al. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA. 2001 ; 285: 2871-2879
37. Smith SA, Shah ND, Bryant SC, Christianson TJ, et al. Chronic care model and shared care in diabetes: randomized trial of an electronic decision support system. Mayo Clin Proc. 2008 ; 83: 747-757
38. Nobels F, Debacker N, Brotons C, et al. Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011 ; 10: 82-82
39. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 ; 28: 88-136
40. Clinical practice recommendations. Diabetes Care. 2007 ; 30: S1 - S103
41. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 ; 25: 1105-1187
42. Eccles MP, Whitty PM, Speed C, et al. A pragmatic cluster randomised controlled trial of a Diabetes Recall And Management system: the DREAM trial. Implement Sci. 2007 ; 2: 6-6
43. Lachin JM Biostatistical methods. New York: John Wiley & Sons ; 2002 :
44. Machin D, Campbell M, Fayers P, et al Sample size tables or clinical studies. Oxford: Blackwell Science ; 1997 :
45. Brohet C, De Backer G, Scheen AJ, et al. Belgian evaluation of screening and treatment of high-risk patients based on waist and age (Best study). Eur J Cardiac Prev Rehab 2005; 12: 280.
46. International Diabetes Federation (IDF) Diabetes Atlas, 2011. 5th edition. http://www.idf.org/diabetesatlas/ (Accessed 26 March 2012).
47. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993 ; 16: 434-444
48. Harris MI Diabetes in America. 2 nd ed. Bethesda, MD: National Diabetes Data Group, 1995. Bethesda, MD: National Diabetes Data Group ; 1995 :
49. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care. 2002 ; 25: 476-481
50. Serrano-Gil M, Jacob S. Engaging and empowering patients to manage their type 2 diabetes, Part 1: a knowledge, attitude, and practice gap?. Adv Ther. 2010 ; 27: 321-333
51. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006 ; 4: 23-31
52. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm. 2006 ; 12: 303-309
53. Hermans MP, Amoussou-Guenou KD, Ahn SA, et al. The elusive type 2 diabetes individual at blood pressure control: A phenotypic study. Diabetes Metab Syndr. 2010 ; 4: 215-219
54. Joseph J, Svartberg J, Njølstad I, et al. Change in cardiovascular risk factors in relation to diabetes status: the Tromso Study. Eur J Cardiovasc Prev Rehabil epub April 2011; doi: 10.1177/1741826711408147.
55. Hermans MP, Castro Cabezas M, Strandberg T, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 ; 26: 445-454
56. The Quality and Outcomes Framework (QOF). 2012. http://www.ic.nhs.uk/ services/national-clinical-audit-support-programme-ncasp/diabetes/ the-national-diabetes-audit-and-other-diabetes-information-sources/ the-quality-and-outcomes-framework-qof. Accessed 26 March 2012.
57. Bailie R, Si D, Connors C, et al. Study protocol: audit and best practice for chronic disease extension (ABCDE) Project. BMC Health Serv Res. 2008 ; 8: 184-184
58. Hermans MP, Ahn SA, Rousseau MF Recent advances in the pathogenesis, prevention and management of type 2 diabetes and its complications. Zimering MB, ed. Croatia: InTech ; 2011: 45-66.
59. Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens. 2008 ; 26: S1 - S14
60. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002 ; 40: 794-811
61. Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004 ; 19: 357-362
62. Owen AJ, Retegan C, Rockell M, et al. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes. Clin Exp Pharmacol Physiol. 2009 ; 36: 643-647
63. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 ; 31: 811-822